Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Non-Small Cell Lung Cancer Excellence Forum

Non-Small Cell Lung Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Lyudmila Bazhenova, MD, University of California San Diego
Videos
The Importance of Biomarker Testing for Patients With NSCLC
01/05/2023
Edward Garon, MD, and Lyudmila Bazhenova, MD, discuss their approaches to biomarker testing for patients newly diagnosed with NSCLC, the role of tissue vs liquid biopsy, and how these biomarkers are used to inform treatment decisions.
Edward Garon, MD, and Lyudmila Bazhenova, MD, discuss their approaches to biomarker testing for patients newly diagnosed with NSCLC, the role of tissue vs liquid biopsy, and how these biomarkers are used to inform treatment decisions.
Edward Garon, MD, and Lyudmila...
01/05/2023
Oncology
Lyudmila Bazhenova, MD, Professor of Medicine at the University of California, San Diego, California
Videos
Dabrafenib Plus Trametinib for Patients With BRAF-V600E Mutated Lung Cancer
12/02/2022
Lyudmila Bazhenova, MD, reviews the treatment options for BRAF mutations in lung cancer, a topic she presented at the 2022 Great Debates & Updates in Lung Cancer meeting in New York.
Lyudmila Bazhenova, MD, reviews the treatment options for BRAF mutations in lung cancer, a topic she presented at the 2022 Great Debates & Updates in Lung Cancer meeting in New York.
Lyudmila Bazhenova, MD, reviews...
12/02/2022
Oncology
Edward Garon, MD, David Geffen School of Medicine - UCLA, Los Angeles, California
Videos
Pembrolizumab Monotherapy for Patients With HighPD-L1 Non-Small Cell Lung Cancer
12/02/2022
Edward Garon, MD, discusses the treatment of patients with non-small cell lung cancer and a PD-L1 expression of ≥50%, a topic he debated at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Edward Garon, MD, discusses the treatment of patients with non-small cell lung cancer and a PD-L1 expression of ≥50%, a topic he debated at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Edward Garon, MD, discusses the...
12/02/2022
Oncology
Lyudmila Bazhenova, MD
Videos
Differentiating Targets and Therapies for Patients With HER2-Mutant Lung Cancer
11/29/2022
Lyudmila Bazhenova, MD, University of California, San Diego, California, discusses the management and treatment of patients with HER2-mutated non-small cell lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung...
Lyudmila Bazhenova, MD, University of California, San Diego, California, discusses the management and treatment of patients with HER2-mutated non-small cell lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung...
Lyudmila Bazhenova, MD,...
11/29/2022
Oncology
Melissa Johnson, MD, Tennessee Oncology
Videos
Tremelimumab Added to Durvalumab and Chemotherapy Demonstrates Long-Term OS Benefit in Metastatic NSCLC
11/11/2022
Melissa Johnson, MD, discusses an OS update from the POSEIDON trial after a median follow-up of approximately 4 years, showing a durable long-term OS benefit by adding tremelimumab to durvalumab and chemotherapy for patients with metastatic...
Melissa Johnson, MD, discusses an OS update from the POSEIDON trial after a median follow-up of approximately 4 years, showing a durable long-term OS benefit by adding tremelimumab to durvalumab and chemotherapy for patients with metastatic...
Melissa Johnson, MD, discusses...
11/11/2022
Oncology
Melissa Johnson, MD, Tennessee Oncology
Videos
Sotorasib Significantly Improves PFS vs Docetaxel in Patients With KRAS G12C-Mutated NSCLC
11/10/2022
Melissa Johnson, MD, discusses results from the phase 3 CodeBreaK 200 trial comparing sotorasib vs docetaxel for patients with previously treated NSCLC with a KRAS G12C mutation.
Melissa Johnson, MD, discusses results from the phase 3 CodeBreaK 200 trial comparing sotorasib vs docetaxel for patients with previously treated NSCLC with a KRAS G12C mutation.
Melissa Johnson, MD, discusses...
11/10/2022
Oncology
Raj Veluswamy, MD, Icahn School of Medicine, New York
Videos
NTRK: Front-Line and Second-Line Treatment Options for Patients With NSCLC
10/15/2022
Rajwanth Veluswamy, MD, provides an overview of his presentation at Great Debates and Updates in Lung Cancer covering front-line and second-line treatment options for patients with NSCLC and NTRK fusions.
Rajwanth Veluswamy, MD, provides an overview of his presentation at Great Debates and Updates in Lung Cancer covering front-line and second-line treatment options for patients with NSCLC and NTRK fusions.
Rajwanth Veluswamy, MD, provides...
10/15/2022
Oncology
Kristin Higgins, MD, Winship Cancer Institute, GA
Videos
SRS and Other Local Ablative Strategies in Patients With NSCLC and Oligometastases
10/15/2022
Dr Kristin Higgins provides an overview of her presentation at Great Debates and Updates in Lung Cancer covering ablative radiation & other local modalities in systemically treated patients with NSCLC and oligometastases.
Dr Kristin Higgins provides an overview of her presentation at Great Debates and Updates in Lung Cancer covering ablative radiation & other local modalities in systemically treated patients with NSCLC and oligometastases.
Dr Kristin Higgins provides an...
10/15/2022
Oncology
Nasser Altorki, MD, Weill Cornell Medical College
Videos
Adjuvant Checkpoint Inhibitors in Resectable NSCLC
10/15/2022
Dr Nasser Altorki reviews his presentation on adjuvant checkpoint inhibitors for patients with resectable non-small cell lung cancer, from the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Dr Nasser Altorki reviews his presentation on adjuvant checkpoint inhibitors for patients with resectable non-small cell lung cancer, from the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Dr Nasser Altorki reviews his...
10/15/2022
Oncology
Pasi Jänne, MD, Dana-Farber Cancer Institute
Videos
Trastuzumab Deruxtecan for HER2-Mutant Non-Small Cell Lung Cancer
09/21/2022
Pasi Jänne, MD, shares insights about the recent FDA approval of trastuzumab deruxtecan for patients with HER2-mutant non-small cell lung cancer and the data that led to this approval.
Pasi Jänne, MD, shares insights about the recent FDA approval of trastuzumab deruxtecan for patients with HER2-mutant non-small cell lung cancer and the data that led to this approval.
Pasi Jänne, MD, shares insights...
09/21/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement